clinical value of serum tumor-associated trypsin inhibitor tati in the diagnosis and follow-up of patients with gynecological tumors

ABSTRACT

To evaluate the serum levels and clinical value of TATI in different gynecological tumors, this study was carried out including 77 cases [40 with different types of gynecological cancer, 22 with benign diseases and 15 normal healthy controls]. Serum TATI was measured using radioimmunoassay [RIA] kit supplied by Farmos diagnostic. The results of the study showed that serum TATI was highly increased in the cancer group compared to either the group of benign diseases or the normal control group. At 100% specificity, TATI showed a sensitivity of about 60% in gynecological tumors as a whole and 73% in the endometrial, 50% in the ovarian and 60% in the cervical tumors. While at a lower specificity [60%], the sensitivity becomes 75% for the whole cancer patients, 91% in the endometrial, 64% in the ovarian and 60% in the cervical tumors. The benign cases showed a false positivity of about 32%. The follow up of certain cases after surgical interference showed that serum TATI is a valuable marker in monitoring these patients